Beispiel Kardiologie: Drug-eluting
|
|
- Coleen Matthews
- 7 years ago
- Views:
Transcription
1 Umsetzung von Studienergebnissen in die klinische Praxis Beispiel Kardiologie: Drug-eluting Stents Wolfgang Rutsch Leiter des Bereichs Herzkatheterlabore Medizinische Klinik mit Schwerpunkt Kardiologie und Angiologie Klinik- und Zentrumsdirektor Prof. Dr. med. Gert Baumann Charité,, Universitätsmedizin tsmedizin Berlin, Campus Charité Mitte Rutsch Charité Aug 28 #1#
2 Entwicklung von PCI und koronarchirurgischen Eingriffen in Deutschland zwischen Jahr 2 Rev Rev PTCA gesamt ACVB CABG (17,6%) PCI PCI (82,4%) Revaskularisationen pro 1 Mill Einwohner: USA Deutschland Jahr Rutsch Charité Aug 28 #2#
3 Angiographic Restenosis in Clinical Trials Author Year n Treatment RR, % Raizner et al Prostacyclin 47 Schwartz et al Aspirin-dipyridamole 39 Ellis et al i.v. heparin 39 M-HEART Corticosteroid 43 Franzen et al Fish oil 35 Knudtson et al Prostacyclin 3 CCAT PTCA vs. DCA 43 CAVEAT PTCA vs. DCA 58 BENEENT I PTCA vs. stent 32 RESS PTCA vs. stent 42 Weintraub et al Lovastatin 41 M-HEART-II Thromboxane antagonist 45 MARCATOR Cilazapril 36 BOAT PTCA vs. DCA 4 BENEENT II PTCA vs. stent 21 TOTAL 38% Rutsch Charité Aug 28 #3#
4 Restenosis Rates in Randomized Trials of DES A hierarchical Bayesion meta-analysis analysis of randomised clinical trials of DES MN Babapulle,, et al. Lancet 24, 364: RAVEL SIRIUS C-SIRIUS E-SIRIUS Pooled Cypher TAXUS I TAXUS II TAXUS IV Pooled -83% TAXUS 6,2 DES -69% 7,1 Cypher BX Velocity BMS 36,9 TAXUS Express 23,5 Rutsch Charité Aug 28 #4#
5 Target Lesion Revascularization Rates in Randomized Trials Investigating DES A hierarchical Bayesion meta-analysis analysis of randomised trials of DES MN Babapulle,, et al. Lancet 24, 364: RAVEL RAVEL SIRIUS SIRIUS C-SIRIUS C-SIRIUS E-SIRIUS E-SIRIUS Pooled Pooled Cypher Cypher TAXUS TAXUS II TAXUS TAXUS II II TAXUS -8% TAXUS IV IV Pooled Pooled TAXUS TAXUS -73% 18,5 12,2 5 3,5 3,3 Cypher BX Velocity TAXUS Express DES BMS Rutsch Charité Aug 28 #5#
6 DES-Thrombose Firestorm ESC Barcelona 2 Camenzind E, ESC 2, Oral Presentation #992 Analyse aller damals verfügbaren, publizierten, randomisierten Studien, Analyse auf Studienebene! Rutsch Charité Aug 28 #6#
7 BASKET-LATE % 1,2 Cardiac death BMS DES 4,9 4,1 1,3 1,3 MI MI Cardiac death and MI MI 6,7 4,5 TVR Late major cardiac events (months 7 to 18). Cardiac death or nonfatal myocardial infarction (MI), was significantly greater in drug-eluting stent (blue) versus bare-metal stent (red) groups, which contrasts with a trend toward a lower restenosis-related related target vessel revascularization (TVR) rate after drug-eluting stents. Rutsch Charité Aug 28 #7#
8 9 Prospective, Double-Blind Blind, Randomized Trials Freedom From Cardiac Death Independent CRF patient-level meta-analysis analysis Rutsch Charité Aug 28 #8#
9 9 Prospective, Double-Blind Blind, Randomized Trials Freedom From Myocardial Infarction Independent CRF patient-level meta-analysis analysis Rutsch Charité Aug 28 #9#
10 9 Prospective, Double-Blind Blind, Randomized Trials Freedom From Ischemic TLR Independent CRF patient-level meta-analysis analysis Rutsch Charité Aug 28 #1#
11 SCAAR Swedish Coronary Angiography and Angioplasty Registry Lagerqvist B, et al, for the SCAAR Study Group, NEJM 27 6-month cumulative incidence of death and myocardial infarction of the cohort of the SCAAR registry. A A Landmark Trial Rutsch Charité Aug 28 #11#
12 SCAAR Swedish Coronary Angiography and Angioplasty Registry Lagerqvist B, et al, for the SCAAR Study Group, NEJM 27 25: 63% 2: 27% Rutsch Charité Aug 28 #12#
13 The SCAAR registry or the Swedish yo-yo Patrick W. Serruys*, MD PhD; ; Joost Daemen,, MD Department of Cardiology,, Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands, EuroIntervention Nov 27 6-month cumulative incidence of death and myocardial infarction of the 25 cohort of the SCAAR registry. A A Landmark Blamage Percentage of DES and BMS use per year in Sweden (SCAAR registry) Rutsch Charité Aug 28 #13#
14 DES Penetration in the US Source: Millenium Research Group BASKET-LATE Sept 2 COURAGE-Trial March Jan 89, 87,9 87,8 88, 87,7 85,9 86,1 83,9 8,1 Feb Mar Apr May Jun Camenzind ESC Barcelona Sept 2 July Aug Sep Oct 76,9 72,8 7,4 7,2 68, 67,9 66,8 65,2 Nov SCAAR-Registry Feb 27 FDA-Panel Dez 2 Dec Jan 7 Feb 7 ACC April 27 64,8 62, Abnahme DES- Implantation Mar Apr May Jun um July3% Sep von 89% Jan 2 auf 62% Sept 27 Rutsch Charité Aug 28 #14#
15 Academic Research Consortium (ARC) Definitions of Stent Thrombosis Timing Acute stent thrombosis: : 24 h after stent implantation Subacute stent thrombosis: : 24 h 3 h d after stent implantation Late : 3 d 1 d 1 y after stent implantation Very late *: 1 y after stent implantation Three categories of evidence in defining stent thrombosis Definite stent thrombosis Probable stent thrombosis Possible Rutsch Charité Aug 28 #15#
16 Academic Research Consortium Definitions of in a Pooled Meta- Analysis of the Randomized RAVEL, SIRIUS, E-SIRIUS, E and C-SIRIUS C Trials Possible Possible Probable Probable Definite Definite Very Very late late (>1year) (>1year) Late Late (<1 (<1 year) year) Subacute Subacute (<3d) (<3d) Acute Acute (<24 (<24 h) h) ARC, ARC, any any thrombosis thrombosis 1,5 1,5 1,9 1,9,9,9,3,3 BMS BMS,8,8 SES 1,1 SES 1,1 1,6 1,6 2,6 2,6 1,3 1,3,3,3,3,3,5,5 3,2 3,2 3,4 3,4,5 1 1,5 2 2,5 3 3,5 4,5 1 1,5 2 2,5 3 3,5 4 Rutsch Charité Aug 28 #16# %
Duration of Dual Antiplatelet Therapy After Coronary Stenting
Duration of Dual Antiplatelet Therapy After Coronary Stenting C. DEAN KATSAMAKIS, DO, FACC, FSCAI INTERVENTIONAL CARDIOLOGIST ADVOCATE LUTHERAN GENERAL HOSPITAL INTRODUCTION Coronary artery stents are
More informationPRECOMBAT Trial. Seung-Whan Lee, MD, PhD On behalf of the PRECOMBAT Investigators
Premier of Randomized Comparison of Bypass Surgery versus Angioplasty Using Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery Disease PRECOMBAT Trial Seung-Whan Lee, MD, PhD On behalf
More informationAT&T Global Network Client for Windows Product Support Matrix January 29, 2015
AT&T Global Network Client for Windows Product Support Matrix January 29, 2015 Product Support Matrix Following is the Product Support Matrix for the AT&T Global Network Client. See the AT&T Global Network
More informationUniversity of Ulsan College of Medicine, Asan Medical Center on behalf of the REAL-LATE and the ZEST-LATE trial
Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation A Pooled Analysis of the REAL-LATE and the ZEST-LATE Trial Seung-Jung Park MD PhD Seung-Jung Park, MD, PhD, University of Ulsan
More informationDrug-Eluting Balloons. Klaus Bonaventura Department of Cardiology and Angiology Heart Thorax Vascular Center, Klinikum Ernst von Bergmann, Potsdam
Drug-Eluting Balloons Klaus Bonaventura Department of Cardiology and Angiology Heart Thorax Vascular Center, Klinikum Ernst von Bergmann, Potsdam Potential conflicts of interest Speaker s name: Klaus Bonaventura
More informationAnalysis One Code Desc. Transaction Amount. Fiscal Period
Analysis One Code Desc Transaction Amount Fiscal Period 57.63 Oct-12 12.13 Oct-12-38.90 Oct-12-773.00 Oct-12-800.00 Oct-12-187.00 Oct-12-82.00 Oct-12-82.00 Oct-12-110.00 Oct-12-1115.25 Oct-12-71.00 Oct-12-41.00
More informationAntonio Colombo MD on behalf of the SECURITY Investigators
Second Generation Drug-Eluting Stents Implantation Followed by Six Versus Twelve-Month - Dual Antiplatelet Therapy - The SECURITY Randomized Clinical Trial Antonio Colombo MD on behalf of the SECURITY
More informationCOMPARISON OF FIXED & VARIABLE RATES (25 YEARS) CHARTERED BANK ADMINISTERED INTEREST RATES - PRIME BUSINESS*
COMPARISON OF FIXED & VARIABLE RATES (25 YEARS) 2 Fixed Rates Variable Rates FIXED RATES OF THE PAST 25 YEARS AVERAGE RESIDENTIAL MORTGAGE LENDING RATE - 5 YEAR* (Per cent) Year Jan Feb Mar Apr May Jun
More informationCOMPARISON OF FIXED & VARIABLE RATES (25 YEARS) CHARTERED BANK ADMINISTERED INTEREST RATES - PRIME BUSINESS*
COMPARISON OF FIXED & VARIABLE RATES (25 YEARS) 2 Fixed Rates Variable Rates FIXED RATES OF THE PAST 25 YEARS AVERAGE RESIDENTIAL MORTGAGE LENDING RATE - 5 YEAR* (Per cent) Year Jan Feb Mar Apr May Jun
More informationLEADERS: 5-Year Follow-up
LEADERS: -Year Follow-up from a Prospective, Randomized Trial of Biolimus A9-eluting Stents with a Biodegradable Polymer vs. Sirolimus-eluting Stents with a Durable Polymer : Final Report of the LEADERS
More informationUsing Clinical Registries to Create Evidence-based Health Care Policy : Experiences from Ontario, Canada
Using Clinical Registries to Create Evidence-based Health Care Policy : Experiences from Ontario, Canada April 2009 Jack V. Tu, MD PhD FRCPC CANADA RESEARCH CHAIR IN HEALTH SERVICES RESEARCH Institute
More informationTherapeutic Approach in Patients with Diabetes and Coronary Artery Disease
Home SVCC Area: English - Español - Português Therapeutic Approach in Patients with Diabetes and Coronary Artery Disease Martial G. Bourassa, MD Research Center, Montreal Heart Institute, Montreal, Quebec,
More informationDual Antiplatelet Therapy. Stephen Monroe, MD FACC Chattanooga Heart Institute
Dual Antiplatelet Therapy Stephen Monroe, MD FACC Chattanooga Heart Institute Scope of Talk Identify the antiplatelet drugs and their mechanisms of action Review dual antiplatelet therapy in: The medical
More informationCopenhagen University Hospital Rigshospitalet Aarhus University Hospital Skejby Denmark
Long-term outcome after drug-eluting versus bare-metal stent implantation in patients with ST-elevation myocardial infarction 3 year follow-up of the randomised trial Peter Clemmensen, Henning Kelbæk,
More informationMEDICAL POLICY No. 91580-R1 DRUG-ELUTING STENTS FOR ISCHEMIC HEART DISEASE
DRUG-ELUTING STENTS FOR ISCHEMIC HEART DISEASE Effective Date: October 1, 2015 Review Dates: 10/11, 10/12, 10/13, 8/14, 8/15 Date Of Origin: October 12, 2011 Status: Current Summary of Changes Clarifications:
More informationCase 2:08-cv-02463-ABC-E Document 1-4 Filed 04/15/2008 Page 1 of 138. Exhibit 8
Case 2:08-cv-02463-ABC-E Document 1-4 Filed 04/15/2008 Page 1 of 138 Exhibit 8 Case 2:08-cv-02463-ABC-E Document 1-4 Filed 04/15/2008 Page 2 of 138 Domain Name: CELLULARVERISON.COM Updated Date: 12-dec-2007
More informationDatabases in Clinical Research. Harvard-MIT Division of Health Sciences and Technology HST.951J: Medical Decision Support
Databases in Clinical Research Harvard-MIT Division of Health Sciences and Technology HST.951J: Medical Decision Support Overview Background: History and utility of clinical data repositories Strategies:
More informationDUAL ANTIPLATELET THERAPY. Dr Robert S Mvungi, MD(Dar), Mmed (Wits) FCP(SA), Cert.Cardio(SA) Phy Tanzania Cardiac Society Dar es Salaam Tanzania
DUAL ANTIPLATELET THERAPY Dr Robert S Mvungi, MD(Dar), Mmed (Wits) FCP(SA), Cert.Cardio(SA) Phy Tanzania Cardiac Society Dar es Salaam Tanzania DUAL ANTIPLATELET THERAPY (DAPT) Dual antiplatelet regimen
More informationEXAMINATION trial. Manel Sabaté Hospital Clínic, Barcelona (On behalf of the Examination Investigators)
EXAMINATION trial Manel Sabaté Hospital Clínic, Barcelona (On behalf of the Examination Investigators) EXAMINATION trial Background and Rationale (I) Acute coronary syndromes repeatedly appear as independent
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationPresenter: Marco Valgimigli, MD PhD, FESC Erasmus MC, Thoraxcenter Rotterdam The Netherlands
Comparing zotarolimus-eluting and bare-metal stent efficacy in selected high bleeding risk patients treated with a short dual antiplatelet therapy duration. A pre-specified analysis from the The Zotarolimuseluting
More informationEnhanced Vessel Traffic Management System Booking Slots Available and Vessels Booked per Day From 12-JAN-2016 To 30-JUN-2017
From -JAN- To -JUN- -JAN- VIRP Page Period Period Period -JAN- 8 -JAN- 8 9 -JAN- 8 8 -JAN- -JAN- -JAN- 8-JAN- 9-JAN- -JAN- -JAN- -JAN- -JAN- -JAN- -JAN- -JAN- -JAN- 8-JAN- 9-JAN- -JAN- -JAN- -FEB- : days
More informationShould EDTA Chelation Therapy be Used Instead of Long-term Clopidogrel plus Aspirin to Treat Patients at Risk from Drug-Eluting Stents?
Should EDTA Chelation Therapy be Used Instead of Long-term Clopidogrel plus Aspirin to Treat Patients at Risk from Drug-Eluting Stents? L. Terry Chappell, MD Abstract The recently discovered increased
More informationCilostazol versus Clopidogrel after Coronary Stenting
Cilostazol versus Clopidogrel after Coronary Stenting Seong-Wook Park, MD, PhD, FACC Division of Cardiology, Asan Medical Center University of Ulsan College of Medicine Seoul, Korea AMC, 2004 Background
More informationIntracoronary Stenting and. Robert A. Byrne, Julinda Mehilli, Salvatore Cassese, Franz-Josef Neumann, Susanne Pinieck, Tomohisa Tada,
Prospective, Randomized Trial of Paclitaxel-Eluting Balloon versus Paclitaxel-Eluting Stent versus Balloon Angioplasty for Treatment of Coronary Restenosis in Limus- Eluting Stents Intracoronary Stenting
More informationBRIGHT Trial. Bivalirudin versus Heparin and Heparin plus Tirofiban in Patients with AMI Undergoing PCI. Thirty-Day and One-Year Outcomes of the
Bivalirudin versus Heparin and Heparin plus Tirofiban in Patients with AMI Undergoing PCI Thirty-Day and One-Year Outcomes of the BRIGHT Trial Yaling Han, MD, FACC On behalf of the BRIGHT investigators
More informationOstial LAD: Single stent approach is the best. Antonio A. Pocoví, MD, FSCAI, MTSAC, Advisory Council Member, CACI
Ostial LAD: Single stent approach is the best Antonio A. Pocoví, MD, FSCAI, MTSAC, Advisory Council Member, CACI Chair, Interventional Cardiology Sanatorio San Lucas Instituto Alexander Fleming Buenos
More informationCoronary Bifurcation Treatment: Update from the European Bifurcation Club. Remo Albiero, MD Ist. Clinico S. Rocco Brescia (Italy)
Coronary Bifurcation Treatment: Update from the European Bifurcation Club Remo Albiero, MD Ist. Clinico S. Rocco Brescia (Italy) Disclosure Statement of Financial Interest Within the past 12 months, I
More informationA Post-market Study to Assess the STENTYS Self-exPanding COronary Stent In AcuTe myocardial InfarctiON in Real Life APPOSITION III
A Post-market Study to Assess the STENTYS Self-exPanding COronary Stent In AcuTe myocardial InfarctiON in Real Life APPOSITION III Gilles Montalescot, MD, PhD Pitié-Salpêtrière Hospital, Paris, France
More informationGetting smart about dyspnea and life saving drug therapy in ACS patients. Kobi George Kaplan Medical Center Rehovot
Getting smart about dyspnea and life saving drug therapy in ACS patients Kobi George Kaplan Medical Center Rehovot 78 year old female Case description Presented with resting chest pain and dyspnea Co morbidities:
More informationAntiaggreganti. STEMI : cosa c è di nuovo? Heartline 2015. Genova 13 14 Novembre 2015
Heartline 2015 Genova 13 14 Novembre 2015 STEMI : cosa c è di nuovo? Antiaggreganti Luigi Oltrona Visconti Divisione di Cardiologia IRCCS Fondazione Policlinico S. Matteo Pavia STEMI : cosa c è di nuovo?
More informationClinical Research Intracoronary Stenting with Crushing in Coronary Artery Bifurcation Lesions: Initial Results and Medium-Term Follow Up
Hellenic J Cardiol 45: 379-383, 2004 Clinical Research Intracoronary Stenting with Crushing in Coronary Artery Bifurcation Lesions: Initial Results and Medium-Term Follow Up PETROS S. DARDAS, DIMITRIS
More informationCENTERPOINT ENERGY TEXARKANA SERVICE AREA GAS SUPPLY RATE (GSR) JULY 2015. Small Commercial Service (SCS-1) GSR
JULY 2015 Area (RS-1) GSR GSR (LCS-1) Texarkana Incorporated July-15 $0.50690/Ccf $0.45450/Ccf $0.00000/Ccf $2.85090/MMBtu $17.52070/MMBtu Texarkana Unincorporated July-15 $0.56370/Ccf $0.26110/Ccf $1.66900/Ccf
More informationJUL 2 2008. Ms. Kendra Basler Regulatory Affairs Associate Abbott Vascular Cardiac Therapies 3200 Lakeside Drive Santa Clara, CA 95054-2807
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service JUL 2 2008 Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850 Ms. Kendra Basler Regulatory Affairs Associate Abbott Vascular
More informationPerspectives on the Selection and Duration of Dual Antiplatelet Therapy
Perspectives on the Selection and Duration of Dual Antiplatelet Therapy Dominick J. Angiolillo, MD, PhD, FACC, FESC, FSCAI Director of Cardiovascular Research Associate Professor of Medicine University
More informationIncidence of stent thrombosis and adverse cardiac events 5 years after sirolimus stent implantation in clinical practice
Interventional Cardiology Incidence of stent thrombosis and adverse cardiac events 5 years after sirolimus stent implantation in clinical practice Jean-Jacques Goy, MD, a Philip Urban, MD, b Urs Kaufmann,
More informationPreoperative Cardiac Stents Perioperative Management. Mark A. Taylor, MD Department of Anesthesia
Preoperative Cardiac Stents Perioperative Management Mark A. Taylor, MD Department of Anesthesia Revasc prior to NCS If it offered long term benefit-- --made sense to do it 1-22 vessel CAD by angiogram,
More informationManagement of acute coronary syndromes in patients presenting without persistent ST-segment elevation
Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation Recommendations of the European Society of Cardiology Updated version December 2002 Task Force on management
More informationHow to manage a patient who needs thrombolysis in acute stroke, ablation or angioplasty/stenting? Janet M McComb Freeman Hospital Newcastle upon Tyne
How to manage a patient who needs thrombolysis in acute stroke, ablation or angioplasty/stenting? Janet M McComb Freeman Hospital Newcastle upon Tyne What do the guidelines say? What happens with warfarin
More informationAntiplatelet and anticoagulation treatment of patients undergoing carotid and peripheral artery angioplasty
Round Table: Antithrombotic therapy beyond ACS Antiplatelet and anticoagulation treatment of patients undergoing carotid and peripheral artery angioplasty M. Matsagkas, MD, PhD, EBSQ-Vasc Associate Professor
More informationObjectives. Preoperative Cardiac Risk Stratification for Noncardiac Surgery. History
Preoperative Cardiac Risk Stratification for Noncardiac Surgery Kimberly Boddicker, MD FACC Essentia Health Heart and Vascular Center 27 th Heart and Vascular Conference May 13, 2011 Objectives Summarize
More informationANESTHESIA FOR PATIENTS WITH CORONARY STENTS FOR NON CARDIAC SURGERY. Dr. Mahesh Vakamudi. Professor and Head
ANESTHESIA FOR PATIENTS WITH CORONARY STENTS FOR NON CARDIAC SURGERY Dr. Mahesh Vakamudi Professor and Head Department of Anesthesiology, Critical Care and Pain Medicine Sri Ramachandra University INTRODUCTION
More informationTranscatheter Cardiovascular Therapeutics 19 th Annual Scientific Symposium October 20-25, 2007
Comparative Late Risk of Death, Myocardial Infarction, and Stent Thrombosis for Bare-Metal and Drug-Eluting Stents: A Landmark Analysis from the STENT Registry Charles Simonton MD, Bruce Brodie MD, Barrett
More informationDéjeuner/Repas Débat ABBOTT «Docteur, je veux un stent qui se dissout» ABSORB,la révolu@on oui, mais chez quel pa@ent? Les dernières données ABSORB
Déjeuner/Repas Débat ABBOTT «Docteur, je veux un stent qui se dissout» ABSORB,la révolu@on oui, mais chez quel pa@ent? Les dernières données ABSORB Didier Carrié CHU Toulouse APPAC 4 Juin 2014 Aucun conflit
More informationAshley Institute of Training Schedule of VET Tuition Fees 2015
Ashley Institute of Training Schedule of VET Fees Year of Study Group ID:DECE15G1 Total Course Fees $ 12,000 29-Aug- 17-Oct- 50 14-Sep- 0.167 blended various $2,000 CHC02 Best practice 24-Oct- 12-Dec-
More informationInvestor science conference call: American College of Cardiology 2015
Investor science conference call: American College of Cardiology 2015 San Diego, California, USA 16 March 2015 Cautionary statement regarding forward-looking statements In order, among other things, to
More informationThe Pantera Lux Paclitaxel DEB Device Description and Clinical Studies. Christoph Hehrlein, University Clinic Freiburg i.br.
The Pantera Lux Paclitaxel DEB Device Description and Clinical Studies Christoph Hehrlein, University Clinic Freiburg i.br. Germany Disclosure Statement of Financial Interest Within the past 12 months,
More information2008 COAP Audit Results & Progress. Kristin Sitcov COAP Program Director
2008 COAP Audit Results & Progress Kristin Sitcov COAP Program Director Audit Rationale Rationale: Popular request Always had inter-rater reliability will continue Way to assess agreement with standards
More informationThe Bioresorbable Vascular Stent Dr Albert Ko
The Bioresorbable Vascular Stent Dr Albert Ko Dr Albert Ko MB BS, FRACP, FCSANZ Interventional/General Cardiologist Ascot Cardiology Symposium 2013 Treatment Goals for Coronary Artery Disease Relieve of
More informationDrug-eluting stents versus bare metal stents for angina or acute coronary syndromes (Review)
Drug-eluting stents versus bare metal stents for angina or acute coronary syndromes (Review) Greenhalgh J, Hockenhull J, Rao N, Dundar Y, Dickson RC, Bagust A This is a reprint of a Cochrane review, prepared
More informationNone. Dual Antiplatelet Therapy Plus Systemic Anticoagulation: Bleeding Risk and Management. 76 year old male LINGO 1/5/2015
Financial Disclosure Information Dual Antiplatelet Therapy Plus Systemic Anticoagulation: Bleeding Risk and Management Robert D. McBane, M.D. Division of Cardiology Mayo Clinic Rochester Dual Antiplatelet
More informationDrug-Eluting Coronary Stents. Paul Montero PGY-II University of Colorado Health Sciences Center Surgical Grand Rounds Resident Debate
Drug-Eluting Coronary Stents Paul Montero PGY-II University of Colorado Health Sciences Center Surgical Grand Rounds Resident Debate Outline Coronary Artery Disease Evolution of Percutaneous Coronary Intervention
More informationέΰζβν αππ έκυ,νσϊίία κν1γν πλδζέκυνβί1γ π ηία δεόμνκαλ δκζόΰκμ, θν δ υγυθ άμνγνκαλ /εάμ ΚζδθδεάμΝ υλωεζδθδεάμν
ΝΠθ ζζάθδκνσθϋ λδκν έΰκ μνεδν ιωθκ κεκη δεάμνι λδεάμ έΰζβν έκ,νσϊίί κν1γν λδζέκνβί1γ Α Α φ ; έζ δκμννένσθόμ ηί δεόμνκλ δκζόΰκμ, θν δ γθ άμνγνκλ /εάμ ΚζδθδεάμΝ λωεζδθδεάμν ένivus Scientific Director, Mediolanum
More informationRepeat Coronary Revascularization Procedures after Successful Bare-Metal or Drug-Eluting Stent Implantation
Original Contribution Repeat Coronary Revascularization Procedures after Successful Bare-Metal or Drug-Eluting Stent Implantation Cynthia A. Yock, MS, J. Michael Isbill, MS, Spencer B. King III, MD, Mark
More informationSAMPLE. Asia-Pacific Interventional Cardiology Procedures Outlook to 2020. Reference Code: GDMECR0061PDB. Publication Date: May 2014
Asia-Pacific Interventional Cardiology Procedures Outlook to 2020 Reference Code: GDMECR0061PDB Publication Date: May 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 4 1.2
More informationResearch Skills for Non-Researchers: Using Electronic Health Data and Other Existing Data Resources
Research Skills for Non-Researchers: Using Electronic Health Data and Other Existing Data Resources James Floyd, MD, MS Sep 17, 2015 UW Hospital Medicine Faculty Development Program Objectives Become more
More informationCORONARY ARTERY BYPASS GRAFTS, STENTS, AND EXTRACORONARY CARDIAC DZ. Charles White MD
CORONARY ARTERY BYPASS GRAFTS, STENTS, AND EXTRACORONARY CARDIAC DZ Charles White MD Director of Thoracic Imaging Department of Radiology University of Maryland CORONARY ARTERY BYPASS GRAFTS First performed
More informationPooled RESOLUTE Clinical Program
The Relationship Between Short and Long-term Antiplatelet Therapy Use and Stent Thrombosis Following Percutaneous Coronary Intervention With the Resolute Zotarolimus-eluting Stent Pooled RESOLUTE Clinical
More informationThe BASE-ACS Trial. A Randomized Comparison of a TITAN-2 BAS with XIENCE-V- EES Stent in Acute Coronary Syndrome. 18 months Follow-up results
The BASE-ACS Trial A Randomized Comparison of a TITAN-2 BAS with XIENCE-V- EES Stent in Acute Coronary Syndrome 18 months Follow-up results Pasi Karjalainen, MD, PhD, adjunct Professor on behalf of the
More informationESC PCI Guidelines: / Sigmund Silber et al. 1
For the first time! ESC PCI Guidelines: / Sigmund Silber et al. 1 in 2002: 649.332 in 2002: 541.964 ESC PCI Guidelines: Introduction and Definitions / Sigmund Silber et al. 2 ESC PCI Guidelines: Introduction
More informationThe Minvasys Amazonia Pax & Nile Pax Polymer Free Paclitaxel Eluting Stent Program
The Minvasys Amazonia Pax & Nile Pax Polymer Free Paclitaxel Eluting Stent Program Jean Fajadet, MD, FESC Clinique Pasteur - Toulouse - France Disclosure statement Nothing to disclose Dedicated Delivery
More informationFFR CT : Clinical studies
FFR CT : Clinical studies Bjarne Nørgaard Department Cardiology B Aarhus University Hospital Skejby, Denmark Disclosures: Research grants: Edwards and Siemens Coronary CTA: High diagnostic sensitivity
More informationIs it really so? : Varying Presentations for ACS among Elderly, Women and Diabetics. Yen Tibayan, M.D. Division of Cardiovascular Medicine
Is it really so? : Varying Presentations for ACS among Elderly, Women and Diabetics Yen Tibayan, M.D. Division of Cardiovascular Medicine Case Presentation 69 y.o. woman calls 911 with the complaint of
More informationWOEST TRIAL- NO ASPIRIN IN STENTED PATIENTS REQUIRING ANTICOAGULATION. Van Crisco, MD, FACC, FSCAI First Coast
WOEST TRIAL- NO ASPIRIN IN STENTED PATIENTS REQUIRING ANTICOAGULATION Van Crisco, MD, FACC, FSCAI First Coast Conflicts of Interest I have been a paid consultant and speaker for AstraZeneca, makers of
More informationPayment policies are potentially a strong driver of diffusion of
Medical Devices Diffusion Of New Technology And Payment Policies: Coronary Stents The implementation of a higher payment rate for stenting did not drive the acceleration of the technology s diffusion,
More informationStent for Life Initiative How can we improve system delay and patients delay in STEMI
Stent for Life Initiative How can we improve system delay and patients delay in STEMI Z. Kaifoszova SFL Initiative Europe 2011 Stent for Life Initiative 10 countries participate in the program Declaration
More information14-Dec-15. Number Amount Number Amount Number Amount Number Amount Number Amount
14-Dec-15 and Number of Qualifying Children, 2013 Returns with no Returns with one Returns with two Returns with three or Size of AGI qualifying children qualifying child qualifying children more qualifying
More informationEquipping your Forecasting Toolkit to Account for Ongoing Changes
Equipping your Forecasting Toolkit to Account for Ongoing Changes Presented by: Roger Parlett Supply Chain Manager January 23, 2014 Overview Forecast Set-up Objectives of Creating a Forecast Identify Critical
More informationStatus of Drug-Eluting Coronary Stents
Status of Drug-Eluting Coronary Stents EVOLUTION OF PERCUTANEOUS CORONARY INTERVENTIONAL TECHNOLOGIES The introduction of percutaneous transluminal coronary angioplasty (PTCA) in the late1970s provided
More informationThe optimal treatment of multivessel coronary artery disease
The optimal treatment of multivessel coronary artery disease The time of ad hoc angioplasty for the patient with multivessel coronary artery disease has passed. James Wilson, Texas Heart Institute. Alexander
More informationPOST STENTING DUAL ANTIPLATELET THERAPY DURATION J BAUCUM MD FACC CAROLINA CARDIOLOGY GHS
POST STENTING DUAL ANTIPLATELET THERAPY DURATION J BAUCUM MD FACC CAROLINA CARDIOLOGY GHS Post Stenting Dual Antiplatelet Therapy When can I stop it? Intracoronary stenting is a frequent intervention for
More informationEuropean Heart Journal (1999) 20, 1014 1019 Article No. euhj.1998.1395, available online at http://www.idealibrary.com on
European Heart Journal (1999) 20, 1014 1019 Article No. euhj.1998.1395, available online at http://www.idealibrary.com on Working Group Report Indications for intracoronary stent placement: the European
More informationAntiplatelet and Antithrombotics From clinical trials to guidelines
Antiplatelet and Antithrombotics From clinical trials to guidelines Ashraf Reda, MD, FESC Prof and head of Cardiology Dep. Menofiya University Preisedent of EGYBAC Chairman of WGLVR One of the big stories
More informationComputing & Telecommunications Services Monthly Report March 2015
March 215 Monthly Report Computing & Telecommunications Services Monthly Report March 215 CaTS Help Desk (937) 775-4827 1-888-775-4827 25 Library Annex helpdesk@wright.edu www.wright.edu/cats/ Last Modified
More informationChristopher M. Wright, MD, MBA Pioneer Cardiovascular Consultants Tempe, Arizona
Christopher M. Wright, MD, MBA Pioneer Cardiovascular Consultants Tempe, Arizona Areas to be covered Historical, current, and future treatments for various cardiovascular disease: Atherosclerosis (Coronary
More informationCardiovascular disease has become a dominant cause of
Abstract Immediate and Six-month Clinical Outcome of Percutaneous Coronary Intervention in a Tertiary Hospital in the Sultanate of Oman Panduranga Prashanth, Mohamed Mukhaini, Abdulla A. Riyami, Kadhim
More informationClinical Programs. Medtronic Coronary Stent Systems. driver BMS
Clinical Programs Medtronic Coronary Stent Systems Endeavor DES driver BMS July 2010 Contents Overview of Clinical Programs... 2 Drug-Eluting Stents ENDEAVOR I*... 4 ENDEAVOR II*... 6 ENDEAVOR II Continued
More informationEarly healing after treatment of coronary lesions by everolimus, or biolimus eluting bioresorbable polymer stents
Early healing after treatment of coronary lesions by everolimus, or biolimus eluting bioresorbable polymer stents One-month results of the study Ida Riise Balleby 1, Trine Krejberg Ørhøj 1, Christian Juhl
More informationGUIDELINES ON MEDICAL DEVICES EVALUATION OF CLINICAL DATA - A GUIDE FOR MANUFACTURERS AND NOTIFIED BODIES -
EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Consumer goods Cosmetics and Medical Devices MEDDEV 2.7.1 Appendix 1 December 2008 GUIDELINES ON MEDICAL DEVICES EVALUATION OF CLINICAL DATA
More informationEnergy Savings from Business Energy Feedback
Energy Savings from Business Energy Feedback Behavior, Energy, and Climate Change Conference 2015 October 21, 2015 Jim Stewart, Ph.D. INTRODUCTION 2 Study Background Xcel Energy runs the Business Energy
More informationIl punto sulla terapia antitrombotica nelle sindromi coronariche acute
Santa Margherita Ligure TIGULLIO CARDIOLOGIA 2012 16-17 Febbrajo 2012 Il trattamento dell infarto miocardico acuto ad ST spraslivellato: dal territorio al laboratorio di emodinamica Il punto sulla terapia
More informationIs There A LIfe for DES after discontinuation of Clopidogrel
Chicago 2014 Is There A LIfe for DES after discontinuation of Clopidogrel Six-month versus 24-month dual antiplatelet therapy after implantation of drug eluting stents in patients non-resistant to aspirin:
More informationPolymer-Based, Paclitaxel-Eluting TAXUS Liberté Stent in De Novo Lesions: The Pivotal TAXUS ATLAS Trial
Polymer-Based, Paclitaxel-Eluting Stent in De Novo Lesions: The Pivotal TAXUS ATLAS Trial Mark A. Turco, John A. Ormiston, Jeffrey J. Popma, Lazar Mandinov, Charles D. O'Shaughnessy, Tift Mann, Thomas
More informationAccident & Emergency Department Clinical Quality Indicators
Overview This dashboard presents our performance in the new A&E clinical quality indicators. These 8 indicators will allow you to see the quality of care being delivered by our A&E department, and reflect
More informationSafe Harbor Statement Writing - Cologuard Cancer
Third-Quarter 2015 Earnings Call October 29, 2015 Safe Harbor statement Certain statements made in this presentation contain forward-looking statements within the meaning of Section 27A of the Securities
More informationDo método diagnóstico ao terapêutico: a História da Hemodinâmica e da Cardiologia Intervencionista, em 15 minutos. Eulógio E Martinez
Do método diagnóstico ao terapêutico: a História da Hemodinâmica e da Cardiologia Intervencionista, em 15 minutos Eulógio E Martinez IVUS vs luminologia Positivo Negativo estenose TCE oclusão CD sístole
More informationNIHI Big Data in Healthcare Research Case Study
NIHI Big Data in Healthcare Research Case Study Professor Rob Doughty Heart Foundation Chair of Heart Health National Institute for Health Innovation and the Dept of Medicine, University of Auckland &
More informationConsumer ID Theft Total Costs
Billions Consumer and Business Identity Theft Statistics Business identity (ID) theft is a growing crime and is a growing concern for state filing offices. Similar to consumer ID theft, after initially
More informationFULL COVERAGE FOR PREVENTIVE MEDICATIONS AFTER MYOCARDIAL INFARCTION IMPACT ON RACIAL AND ETHNIC DISPARITIES
FULL COVERAGE FOR PREVENTIVE MEDICATIONS AFTER MYOCARDIAL INFARCTION IMPACT ON RACIAL AND ETHNIC DISPARITIES Niteesh K. Choudhry, MD, PhD Harvard Medical School Division of Pharmacoepidemiology and Pharmacoeconomics
More informationCAFIS REPORT 2015.10
CAFIS REPORT 2015.10 INDEX Message CAFIS Inbound 03-06 07-08 CAFIS Arch 09-10 CAFIS Brain 11-12 CAFIS Global 13-14 What We Do 15-16 About CAFIS 17-18 Services for Member Stores 19-34 Services for Card
More informationClinical Results of Unprotected Left Main Coronary Stenting
Original Articles IMAJ VOL 11 MARCH 2009 Clinical Results of Unprotected Left Main Coronary Stenting Itsik Ben-Dor MD, Hana Vaknin-Assa MD, Eli Lev MD, David Brosh MD, Shmuel Fuchs MD, Abid Assali MD and
More informationA!Team!Cymru!EIS!Report:!Growing!Exploitation!of!Small! OfCice!Routers!Creating!Serious!Risks!
ATeamCymruEISReport:GrowingExploitationofSmall OfCiceRoutersCreatingSeriousRisks PoweredbyTeamCymru sthreatintelligencegroup Page 1of 14www.team-cymru.com www.team-cymru.com Threat'Intelligence'Group EXECUTIVE
More informationRivaroxaban for acute coronary syndromes
Northern Treatment Advisory Group Rivaroxaban for acute coronary syndromes Lead author: Nancy Kane Regional Drug & Therapeutics Centre (Newcastle) May 2014 2014 Summary Current long-term management following
More informationNew Approaches to, and Indications for, Antiplatelet Therapy
New Approaches to, and Indications for, Antiplatelet Therapy Kenneth A. Bauer, MD Professor of Medicine, Harvard Medical School Chief, Hematology Section, VA Boston Healthcare System Director, Thrombosis
More informationPlatelet Function Testing vs Genotyping : Focus on Pharmacogenomics of Clopidogrel. Kiyuk Chang, M.D., Ph.D.
Platelet Function Testing vs Genotyping : Focus on Pharmacogenomics of Clopidogrel Kiyuk Chang, M.D., Ph.D. Cardiovascular Center & Cardiology Division Seoul St. Mary s Hospital The Catholic University
More informationMalmö Preventive Project. Cardiovascular Endpoints
Malmö Preventive Project Department of Clinical Sciences Malmö University Hospital Lund University Malmö Preventive Project Cardiovascular Endpoints End of follow-up: 31 Dec 2008 * Report: 21 June 2010
More informationMajestic Trial 12 Month Results
Majestic Trial 12 Month Results S.Müller-Hülsbeck, MD, EBIR, FCIRSE, FICA ACADEMIC HOSPITALS Flensburg of Kiel University Ev.-Luth. Diakonissenanstalt zu Flensburg Knuthstraße 1, 24939 FLENSBURG Dept.
More informationMANAGEMENT AKUTES KORONARSYNDROM: RISIKOSTRATIFIZIERUNG UND THERAPIE. Peter Wenaweser Universitätsklinik für Kardiologie
MANAGEMENT AKUTES KORONARSYNDROM: RISIKOSTRATIFIZIERUNG UND THERAPIE Peter Wenaweser Universitätsklinik für Kardiologie Scientific Advances & Cardiovascular Mortality 1950 to 2010 Nabel EM and Braunwald
More informationACC/AHA 2009 STEMI Guideline Focused Update and What s New in 2012 Guideline
ACC/AHA 2009 STEMI Guideline Focused Update and What s New in 2012 Guideline David Zhao, MD, FACC, FSCAI Professor of Medicine and Cardiac Surgery Harry and Shelley Page Professor in Interventional Cardiology
More informationCARDIA 288 MONTH FOLLOW-UP SUPPLEMENTAL FORM (FORM B) HOSPITALIZATION CASE #: INTERVIEWER ID FY288BIVID2. Page 1 of 6 FY288BH4CN
HOSPITALIZATION CASE #: 2 8 8 0 H FY288BH4CN Has the participant indicated any of the following reasons for being admitted overnight for this case? 1. Suspected or confirmed problems with the heart, circulation,
More information